maximum therapeutic effect achieved Jumping to higher doses too quickly is the most common cause of GI discomfort
Lack of Human Clinical Data The most significant limitation is the near-complete absence of published human clinical trial data: No peer-reviewed human efficacy trials exist in scientific literature as of 2025 One analog compound (CB4211) completed Phase 1 safety testing, but results not published in peer-reviewed journals Human optimal dosing, safety profile, and efficacy completely unestablished Long-term effects of exogenous MOTS-c administration in humans unknown No published data on human absorption, distribution, metabolism, or excretion While endogenous MOTS-c levels have been measured in human populations and exercise studies confirm its physiological presence, therapeutic use remains entirely experimental
Nausea: The delay in gastric emptying and the impact on gut hormones can trigger nausea, particularly when starting the medication or when the dose is increased
Christou GA, Katsiki N, Blundell J (2019) Semaglutide as a promising antiobesity drug
Jorns, MS (22 July 2014)
What does the Phase II trial data show
